title: Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
abstract: A total of 72 patients with Ph-positive CML in first chronic phase were followed during a 6-year period in two different institutions in México. Among them, 22 were given a reduced-intensity allogeneic SCT, whereas 50 were given a tyrosine kinase inhibitor (TKI), mainly imatinib mesylate. The 6-year overall survival (OS) after the therapeutic intervention for patients allografted or given a TKI was 77 and 84%, respectively (P, NS); the median OS for both groups has not been reached, being above 90 and 71 months, respectively (P, NS). The freedom from progression to blast or accelerated phases was also similar for both groups, as well as the overall OS after diagnosis. Most patients allografted (91%) chose this treatment because they were unable to afford continuing treatment with the TKI, whereas most treated with the TKI (84%) were given the treatment without charge, through institutions able to pay for their treatment. The median cost of each nonmyeloablative allograft was US$18,000, an amount that is enough to cover 180 days of treatment with imatinib (400 mg per day) in México. Cost considerations favor allogeneic SCT as a 'once only' procedure whereas lifelong treatment with an expensive drug represents an excessive burden on resources.
authors.affiliation: Centro de Hematología y Medicina Interna, Clinica Ruiz, Puebla, México. gruiz1@clinicaruiz.com
authors.forename: G J
authors.initials: GJ
authors.lastname: Ruiz-Argüelles
authors.forename: L C
authors.initials: LC
authors.lastname: Tarin-Arzaga
authors.forename: M L
authors.initials: ML
authors.lastname: Gonzalez-Carrillo
authors.forename: K I
authors.initials: KI
authors.lastname: Gutierrez-Riveroll
authors.forename: R
authors.initials: R
authors.lastname: Rangel-Malo
authors.forename: C H
authors.initials: CH
authors.lastname: Gutiérrez-Aguirre
authors.forename: O G
authors.initials: OG
authors.lastname: Cantú-Rodríguez
authors.forename: D
authors.initials: D
authors.lastname: Gómez-Almaguer
authors.forename: S
authors.initials: S
authors.lastname: Giralt
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides; D002648:Child; D003362:Cost-Benefit Analysis; D003906:Developing Countries / Q000191:economics; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000191:economics / Q000628:therapy*; D008297:Male; D008800:Mexico; D008875:Middle Aged; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use*; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000191:economics
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate